Unnamed "lobbyists" say one thing -- I say, let's give the guy a chance.
Here's what CongressDaily has to say:
Drug industry is wary of Obama's pick for FDA deputy
By Anna Edney, CongressDaily
Food, pharmaceutical and medical device groups have lauded President Obama's pick to lead the Food and Drug Administration, but his selection for second in command is giving the drug industry heartburn.
Industry insiders describe their colleagues as cautiously optimistic about FDA Administrator-nominee Margaret Hamburg, a former New York City health commissioner who works at a nuclear nonproliferation think tank, and nervous in varying degrees about Baltimore City Health Commissioner Joshua Sharfstein.
"
"Companies are clearly going to get more scrutiny."
The drug industry is viewing the dual picks, as one FDA lawyer put it, as a "power-sharing agreement."
Obama emphasized food safety when he announced the selections of
Sharfstein, on the other hand, has a long and sometimes contentious history with the pharmaceutical industry.
"Anyone who spent their career under Henry Waxman ...," said one lobbyist, trailing off with a shudder.
Sharfstein worked under the now-House Energy and Commerce chairman from July 2001 to December 2005, a Waxman spokeswoman said.
Waxman has been tough on drug companies, particularly given several scandals involving contaminated drugs or unheeded warnings in the recent years. Sharfstein has carried the torch on many of his former boss' public health priorities, ranging from cracking down on medication use for illnesses not approved by FDA to criticizing pharmaceutical companies for gifts handed out to physicians.
Sharfstein led the Obama transition team's FDA evaluation and was thought by many to be a shoo-in for the top post at the agency. He raised warning bells as well that led the agency to re-evaluate the safety of cough and cold medicine use for children.
The pediatrician could play a key role implementing 2007 FDA legislation that set up a system for pharmaceutical companies to assess risks associated with their products and come up with a plan to mitigate those risks -- hence the term risk evaluation and mitigation strategy, or REMS. The law affords FDA the discretion to determine how stringent a product's REMS should be, and the drug world fears potentially burdensome REMS could become the norm.
"I think companies are really nervous based on his track record," an industry insider said.
Peter Pitts, co-founder of the Center for Medicine in the Public Interest and a former FDA associate commissioner for external relations, argued the drug lobby's fears are unfounded.
"I don't think you'll see more strident regulations," Pitts said. "I think you'll see a more effective way to use existing regulations."
He anticipates FDA will experience an influx of resources this year that will have the underfunded agency running smoother and more efficiently.
One lobbyist called the new funding on the horizon "a blessing and a curse," adding, "With that money, the question is: What type of additional oversight or regulatory burden [is] not going to be put on just pharma-companies but biotech and medical device companies as well?"
Waxman is a leader in trying to move legislation that would grant FDA the authority to oversee tobacco, a bill Sharfstein worked on with the chairman, as well as his most recent legislation that would allow FDA to approve generic versions of biologic drugs.
